DC ChemicalsChemicals for Life Science
sales@dcchemicals.com

DC60213 · Updated 24 October 2026

DOTMA
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

Literature-reported formulation composition

Componentmol%Role
DOTMA50cationic_lipid
DPPC19.5Helper phospholipid
cholesterol30Sterol
DSPE-PEG(2k)-OMe0.5PEG lipid
Reported total100Source values retained
Formulation calculator unavailable. Disabled: no RNA/N:P or lipid:cargo mass ratio; PEG identity/MW and coadministration setup do not support weighing. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Not reported in the cited article
25 mM sodium acetate pH 4.0,5% glucose vehicle
No nucleic-acid cargo; influenza split-vaccine antigen coadministered.
Subcutaneous tail base; separate IV/SC DiR study
0.5 microgram HA/mouse + 100 microgram LNP in 80 microlitre 5% glucose, twice at 21-day intervals
Male C57BL/6J mice; n=5/group immune panels; n=3–5 AST/ALT
10 mg/mL ethanol lipid solution + 25 mM sodium acetate pH 4.0; NanoAssemblr; 1:3 ethanol:aqueous; total 12 mL/min.

Literature-reported performance for the cited formulation

Literature-reportedHigher SV-specific total IgG, IgG1, IgG2b and IgG2c versus SV alone/comparatorsTwo SC vaccinations; blood day 28; Figs. 2–4
Literature-reportedIFN-gamma 60-fold higher than SV + CpG ODN group; IL-2 higher than CpG ODN or alumSplenocytes 10 days after boost; Fig. 4
Literature-reportedHomologous and heterologous influenza challenge protection reported; graph values not reconstructedMouse challenge; Fig. 5
Literature-reportedNo significant spleen-weight, IL-6/IL-12 p40 or AST/ALT increase versus stated controlsSC adjuvant conditions; Fig. 6
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetKawai A, Noda M, Hirata H, et al. ACS Nano. 2024;18(26):16589–16609.
Formulation and performance source locations are listed with the evidence items above.

PMC full article · Europe PMC XML · DOI · ACS SI (403)